Solicitor General, Generics Makers Rally Behind Sandoz in Biosimilar Case

The U.S. solicitor general and several generics makers have filed U.S. Supreme Court briefs in support of reversing a Federal Circuit ruling that orders sponsors to wait six months after an FDA approval to launch a biosimilar.
Source: Drug Industry Daily